BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Patient Worthy - ECPv5.12.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Patient Worthy
X-ORIGINAL-URL:https://patientworthy.com
X-WR-CALDESC:Events for Patient Worthy
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230214T130000
DTEND;TZID=America/New_York:20230214T140000
DTSTAMP:20261016T035036
CREATED:20230203T142637Z
LAST-MODIFIED:20230203T142637Z
UID:3484291-1676379600-1676383200@patientworthy.com
SUMMARY:The FSHD Society's FSHD University: The FORTITUDE Trial
DESCRIPTION:FSHD University: The FORTITUDE Trial\nFebruary 14\, 2023 \nAvidity Biosciences has announced its plans to launch FORTITUDE\, a Phase 1 / 2 clinical trial in FSHD of the novel compound AOC 1020. This will be the first human trial of an FSHD disease-modifying drug based on an siRNA targeting DUX4 mRNA. We’ll learn more about how the drug works\, the design of the trial\, and where and when patients can expect to enroll in it. \nTo sign up\, click here.
URL:https://patientworthy.com/event/the-fshd-societys-fshd-university-fortitude-trial/
CATEGORIES:Facioscapulohumeral muscular dystrophy
END:VEVENT
END:VCALENDAR